


NR^a, -CO-, -SO-, or -SO₂-; Z is a bond, O, NHSO₂, or NHCO; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.


[0006a] In one aspect, there is provided a compound of Formula I as described herein, wherein a dashed line represents the presence or absence of a bond; A¹ is CR¹, NR^{1A}, or N; A² is NR^{2A}; B¹ is CR⁵ or N; B² is CR⁶ or N; B³ is CR⁷ or N; R¹ is independently F, Cl, Br, I, NO₂, CN, R^a, -OR^a, -NR^{aR^b}, -NHCOR^a, -NH₂SO₂R^a, -OCOR^a, or -SO₂R^a; X is O, NR^a, -CO-, -SO-, or -SO₂-, -CONR^a, hydrocarbyl, and R³ is H or C₁₋₃₀ organyl; or X-R³ is F or Cl; R^{1A}, R^{2A}, R⁴, R^a, and R^b are independently H or C₁₋₃₀ organyl; R⁵, R⁶, and R⁷ are independently F, Cl, Br, I, NO₂, CN, R^a, -OR^a, -NR^{aR^b}, -NHCOR^a, -NH₂SO₂R^a, -OCOR^a, -CONR^{aR^b}, -CO₂R^a, -SO₂R^a, -SO₂NHR^a, or -X¹-(C_mH_{2m}O₀₋₁)-Z-(C_nH_{2n+1}), -(C_mH_{2m}O₀₋₁)-Z-(C_nH_{2n+1}), wherein R⁵ and R⁶ or R⁶ and R⁷ can be optionally linked to form a ring; wherein X¹ is a bond, O, NR^a, -CO-, -SO-, or -SO₂-; Z is a bond, O, NHSO₂, or NHCO; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23, wherein C₁₋₃₀ organyl is an optionally substituted organic substituent group having a free valence at a carbon, selected from the group consisting of optionally substituted C₁₋₃₀ alkyl, optionally substituted C₂₋₁₂ alkenyl, optionally substituted C₂₋₁₂ alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, CN, C(O)R^a, C(O)OR^a, C(O)NHR^a, -C(O)NR^{aR^b}, -C(O)-Z¹-organyl, -C(R^aR^b)-OR^a, -C(R^aR^b) and -NR^{aR^b}, wherein Z¹ is a bond, O, S, or NR^{aR^b} and R^a and R^b is independently H or C₁₋₃₀ hydrocarbyl, wherein the optional substitution comprises halogen, hydroxyl, amine, alkoxy, aryl heteroaryl, sulfone, sulfonamide, carboxylic acid, amide, reversed amide, ester, cycloalkyl, heterocycloalkyl, carbonyl, alkyl, alkenyl, alkynyl, phosphonamidic acid, phosphinic amide, or phosphine oxide.

[0007] Some embodiments include a pharmaceutical dosage form comprising a subject compound. A subject compound or a subject composition may be used for activating TLR7/8. In addition to its use as a stand-alone immunotherapeutic agent, such as an antiviral and anticancer agent, a subject compound or composition may be used as adjuvants in cancer vaccine or adoptive T cell transfer protocols.


[0007a] In another aspect, there is provided a compound which is




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,





a salt of any of these compounds, or an ester of any of these compounds having an -OH group.

[0007b] In yet another aspect, there is provided a compound which is optionally substituted 9-methoxy-1*H*-imidazo[4,5-*c*]quinolin-4-amine.

[0008] Some embodiments include a method of treating a disease or disorder associated with a TLR7/8 agonist comprising administering an effective amount of a subject compound to a mammal in need thereof.

[0009] Some embodiments include use of a subject compound in the manufacture of a medicament for the treatment of a disease or disorder associated with a TLR7/8 agonist.

[0009a] In one aspect, there is provided a dosage form to be administered to a mammal, comprising a compound as described herein.


DETAILED DESCRIPTION OF THE INVENTION

[0010] Unless otherwise indicated, when a compound or chemical structural feature, such as alkyl, alkenyl, alkynyl, aryl, heteroaryl, etc., is referred to as being “optionally substituted,” it includes a feature that has no substituents (i.e. unsubstituted), or a feature that is “substituted,” meaning that the feature has one or more substituents. The term “substituent” has the broadest meaning known to one of ordinary skill in the art, and includes a moiety that occupies a position normally occupied by one or more hydrogen atoms attached to a parent compound or structural feature. In some embodiments, a substituent may be an ordinary organic moiety known in the art, which may have a molecular weight (e.g. the sum of the atomic masses of the atoms of the substituent) of 15-50 g/mol, 15-100 g/mol, 15-150 g/mol, 15-200 g/mol, 15-300 g/mol, or 15-500 g/mol. In some embodiments, a substituent comprises, or consists of: 0-30, 0-20, 0-10, or 0-5 carbon atoms; and 0-30, 0-20, 0-10, or 0-5 heteroatoms, wherein each heteroatom may independently be: N, O, S, Si, F, Cl, Br, or I; provided that the substituent includes one C, N, O, S, Si, F, Cl, Br, or I atom. Examples of substituents include, but are not limited to, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, acyl, acyloxy, alkylcarboxylate, thiol, alkylthio, cyano, halo, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxyl, trihalomethanesulfonyl, trihalomethanesulfonamido, amino, etc.


[0011] For convenience, the term “molecular weight” is used with respect to a moiety or part of a molecule to indicate the sum of the atomic masses of the atoms in the moiety or part of a molecule, even though it may not be a complete molecule.

optionally substituted alkynyl, e.g. optionally substituted C₂₋₁₂ or C₂₋₆ alkynyl, including ethynyl, C₃ alkynyl, C₄ alkynyl, C₅ alkynyl, C₆ alkynyl, C₇ alkynyl, C₈ alkynyl, C₉ alkynyl, C₁₀ alkynyl, C₁₁ alkynyl, C₁₂ alkynyl, C₅ cycloalkynyl, C₆ cycloalkynyl, C₇ cycloalkynyl, C₈ cycloalkynyl, C₉ cycloalkynyl, C₁₀ cycloalkynyl, C₁₁ cycloalkynyl, C₁₂ cycloalkynyl, etc.; optionally substituted aryl, such as optionally substituted phenyl, optionally substituted naphthyl, etc.; optionally substituted heterocyclyl, optionally substituted heteroaryl, etc.; organyl also includes CN, -C(O)R^a, -C(O)OR^a, -C(O)NHR^a, -C(O)NR^aR^b, -C(O)-Z¹-organyl, wherein Z¹ is a bond, O, S, or NR^aR^b, -C(R^aR^b)-OR^a, -C(R^aR^b)-NR^aR^b. In some embodiments, R^a or R^b is independently H or C₁₋₃₀ hydrocarbyl, such as alkyl, alkenyl, alkynyl, or phenyl. In some embodiments, C₁₋₃₀ organyl can be substituted by halogen, hydroxyl, amines, alkoxy, aryl, heteroaryl, sulfone, sulfonamide, carboxylic acid, amide, reversed amide, ester, cycloalkyl, heterocycloalkyl, carbonyl, alkyl, alkenyl, alkynyl, phosphonamidic acid, phosphinic amide, or phosphine oxide.

[0023] Some embodiments include a compound of Formula 2 or Formula 2A.



Formula 2



Formula 2A

[0024] With respect to any relevant structural representation, such as Formula 1, 1A, 1B, 2, or 2A, B¹ is CR⁵ or N. In some embodiments, B¹ is CR⁵. In some embodiments, B¹ is N.


[0025] With respect to any relevant structural representation, such as Formula 1, 1A, 1B, 2, or 2A, B² is CR⁶ or N. In some embodiments, B² is CR⁶. In some embodiments, B² is N.

[0026] With respect to any relevant structural representation, such as Formula 1, 1A, 1B, 2, or 2A, B³ is CR⁷ or N. In some embodiments, B³ is CR⁷. In some embodiments, B³ is N.

[0027] Some embodiments include a compound of Formula 3A, 3B, 3C, 3D, 3E, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13.

WHAT IS CLAIMED IS:

1. A compound represented by a formula:



wherein a dashed line represents the presence or absence of a bond;

A¹ is CR¹, NR^{1A}, or N;

A² is NR^{2A};

B¹ is CR⁵ or N;

B² is CR⁶ or N;

B³ is CR⁷ or N;

R¹ is independently F, Cl, Br, I, NO₂, CN, R^a, -OR^a, -NR^aR^b, -NHCOR^a, -NHCO₂R^a, -OCOR^a, or -SO₂R^a;

X is O, NR^a, -CO-, -SO-, or -SO₂-, -CONR^a, hydrocarbonyl, and R³ is H or C₁₋₃₀ organyl; or X-R³ is F or Cl;

R^{1A}, R^{2A}, R⁴, R^a, and R^b are independently H or C₁₋₃₀ organyl;

R⁵, R⁶, and R⁷ are independently F, Cl, Br, I, NO₂, CN, R^a, -OR^a, -NR^aR^b, -NHCOR^a, -NHCO₂R^a, -OCOR^a, -CO₂R^a, -CONR^aR^b, -SO₂R^a, -SO₂NHR^a, or -X¹-(C_mH_{2m}O₀₋₁)-Z-(C_nH_{2n+1}), -(C_mH_{2m}O₀₋₁)-Z-(C_nH_{2n+1}), wherein R⁵ and R⁶ or R⁶ and R⁷ can be optionally linked to form a ring;

wherein X¹ is a bond, O, NR^a, -CO-, -SO-, or -SO₂;

Z is a bond, O, NHCO₂, or NHCO;


m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23,

wherein C₁₋₃₀ organyl is an optionally substituted organic substituent group having a free valence at a carbon, selected from the group consisting of optionally substituted C₁₋₃₀ alkyl, optionally

substituted C₂₋₁₂ alkenyl, optionally substituted C₂₋₁₂ alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, CN, C(O)R^a, C(O)OR^a, C(O)NHR^a, -C(O)NR^aR^b, -C(O)-Z¹-organyl, -C(R^aR^b)-OR^a, -C(R^aR^b) and -NR^aR^b, wherein Z¹ is a bond, O, S, or NR^aR^b and R^a and R^b is independently H or C₁₋₃₀ hydrocarbyl, wherein the optional substitution comprises halogen, hydroxyl, amine, alkoxyl, aryl heteroaryl, sulfone, sulfonamide, carboxylic acid, amide, reversed amide, ester, cycloalkyl, heterocycloalkyl, carbonyl, alkyl, alkenyl, alkynyl, phosphonamidic acid, phosphinic amide, or phosphine oxide.

2. The compound of claim 1 further represented by a formula:



or a salt thereof, wherein R³ is C₁₋₃₀ organyl.

3. The compound of claim 1 or 2, wherein R¹ or R^{1A} is C₁₋₁₂ optionally substituted alkyl.
4. The compound of claim 3, wherein R¹ or R^{1A} is -C_rH_{2r+1}O, or an ester thereof, wherein r is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
5. The compound of claim 4, wherein R¹ or R^{1A} is -C₃H₇O.
6. The compound of claim 5, wherein R¹ or R^{1A} is -CH₂OCH₂CH₃.
7. The compound of any one claims 1 to 6, wherein R^{2A} is H or C₁₋₁₂ optionally substituted alkyl.
8. The compound of claim 7, wherein R^{2A} is C₁₋₆ alkyl, or -C_yH_{2y+1}O or an ester thereof, wherein y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
9. The compound of claim 8, wherein R^{2A} is CH₃.
10. The compound of claim 7, wherein R^{2A} is H.


11. The compound of claim 7, wherein R^{2A} is C_4H_9 .
12. The compound of any one of claims 1 to 11, wherein R^3 is C_{1-30} optionally substituted alkyl.
13. The compound of claim 12, wherein R^3 is C_{1-10} alkyl, or $-C_wH_{2w+1}O$ or an ester thereof, wherein w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
14. The compound of any one of claims 1 to 12, wherein R^3 is $-(C_tH_{2t}O_{0-1})-Ht$, wherein t is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and Ht is optionally substituted C_{3-6} heterocycl.
15. The compound of any one of claims 1 to 12, wherein R^3 is $-(C_uH_{2u}O_{0-1})-Z-(C_vH_{2v+1})$, wherein Z is a bond, O, $NHSO_2$, or $NHCO$, u is 0, 1, 2, 3, 4, 5, or 6, and v is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.
16. The compound of any one of claims 1 to 12, wherein R^3 is $-(C_uH_{2u}O_{0-1})-NR^aR^b$, and u is 1, 2, 3, 4, 5, or 6, wherein R^a and R^b are independently H or C_{1-6} alkyl.
17. The compound of claim 13, wherein R^3 is $C_5H_{11}O$.
18. The compound of claim 17, wherein R^3 is $-CH_2-CH_2-C(CH_3)_2OH$.
19. The compound of claim 16, wherein R^3 is $-CH_2-CH_2-CH_2-NH_2$.
20. The compound of any one of claims 1 to 19, wherein R^4 is H or C_{1-6} alkyl.
21. The compound of claim 20, wherein R^4 is H.
22. The compound of any one of claims 1 to 21, wherein R^5 is R^a , F, Cl, $-CO_2R^a$, $-CONR^aR^b$, CN, $-OR^a$, $-NR^aR^b$, $-OCOR^a$, or $-SO_2R^a$, $-SO_2NHR^a$, wherein R^a and R^b are independently H or C_{1-6} alkyl.
23. The compound of claim 22, wherein R^5 is H.
24. The compound of any one of claims 1 to 19, wherein R^5 is $-(C_mH_{2m}O_{0-1})-Z-(C_nH_{2n+1})$, wherein Z is a bond, O, $NHSO_2$, or $NHCO$, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23.
25. The compound of any one of claims 1 to 24, wherein R^6 is R^a , F, Cl, $-CO_2R^a$, $-CONR^aR^b$, CN, $-OR^a$, $-NR^aR^b$, $-OCOR^a$, or $-SO_2R^a$, $-SO_2NHR^a$, wherein R^a and R^b are independently H or C_{1-6} alkyl.
26. The compound of claim 25, wherein R^6 is H.
27. The compound of any one of claims 1 to 24, wherein R^6 is $-(C_mH_{2m}O_{0-1})-Z-(C_nH_{2n+1})$, wherein Z is a bond, O, $NHSO_2$, or $NHCO$, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.

28. The compound of any one of claims **1** to **27**, wherein R^7 is R^a , F, Cl, $-\text{CO}_2R^a$, $-\text{CONR}^aR^b$, CN, $-\text{OR}^a$, $-\text{NR}^aR^b$, $-\text{OCOR}^a$, or $-\text{SO}_2R^a$, $-\text{SO}_2\text{NHR}^a$, wherein R^a and R^b are independently H or C_{1-6} alkyl.


29. The compound of claim **28**, wherein R^7 is H.

30. The compound of any one of claims **1** to **27**, wherein R^7 is $-(\text{C}_m\text{H}_{2m}\text{O}_{0-1})-\text{Z}-(\text{C}_n\text{H}_{2n+1})$, wherein Z is a bond, O, NHSO_2 , or NHCO , m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.


31. The compound of any one of claims **1** to **30**, having the structure of Formula 4, 5, 6, 7, 8, 9, or 10,




Formula 4




Formula 5




Formula 6




Formula 7



Formula 8



Formula 9




Formula 10,

wherein R^8 is H, OH, or CH_3 .


32. The compound of claim **31**, wherein R^8 is OH.

33. The compound of claim **31**, wherein R^8 is H.


34. A compound, which is:




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,





a salt of any of these compounds, or an ester of any of these compounds having an -OH group.

35. The compound of claim 1, wherein the compound is an optionally substituted 9-methoxy-1*H*-imidazo[4,5-*c*]quinolin-4-amine.

36. The compound of claim 35, which is optionally substituted 1-(4-amino-2-(ethoxymethyl)-9-methoxy-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-2-methylpropan-2-ol or a salt thereof; optionally substituted 2-(ethoxymethyl)-1-isobutyl-9-methoxy-1*H*-imidazo[4,5-*c*]quinolin-4-amine or a salt thereof; optionally substituted 1-(4-amino-9-methoxy-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-2-methylpropan-2-ol or a salt thereof; optionally substituted 1-(4-amino-2-(2-hydroxyethyl)-9-methoxy-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-2-methylpropan-2-ol or a salt thereof; optionally substituted 4-((4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-9-yl)oxy)-2-methylbutan-2-ol or a salt thereof; optionally substituted 2-(ethoxymethyl)-9-(isopentyloxy)-1*H*-imidazo[4,5-*c*]quinolin-4-amine or a salt thereof; optionally substituted 4-((4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-9-yl)oxy)butan-2-ol or a salt thereof; optionally substituted 1-((4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-9-yl)oxy)propan-2-ol or a salt thereof; optionally substituted 4-((4-amino-2-(2-methoxyethyl)-1*H*-

imidazo[4,5-c]quinolin-9-yl)oxy)-2-methylbutan-2-ol or a salt thereof; optionally substituted 4-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)-2-methylbutan-2-ol or a salt thereof; optionally substituted 2-(ethoxymethyl)-9-(2-isopropoxyethoxy)-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted 4-((4-amino-2-(ethoxymethyl)-1-isobutyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)-2-methylbutan-2-ol or a salt thereof; optionally substituted 2-(ethoxymethyl)-1-(2-isopropoxyethyl)-9-methoxy-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted 4-(4-amino-2-(ethoxymethyl)-9-methoxy-1*H*-imidazo[4,5-c]quinolin-1-yl)-2-methylbutan-2-ol or a salt thereof; optionally substituted 2-(ethoxymethyl)-9-isobutoxy-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted 2-(ethoxymethyl)-9-(2-isopropoxyethoxy)-1-methyl-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted 2-(ethoxymethyl)-9-(isopentyloxy)-1-methyl-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted 2-(ethoxymethyl)-9-isobutoxy-1-methyl-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted *N*-(3-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)propyl)methanesulfonamide or a salt thereof; optionally substituted *N*-(2-(2-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)ethoxy)ethyl)-methanesulfonamide or a salt thereof; optionally substituted *N*-(3-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)propyl)acetamide or a salt thereof; optionally substituted *N*-(4-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)butyl)methanesulfonamide or a salt thereof; optionally substituted *N*-(3-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)propyl)stearamide or a salt thereof; optionally substituted *N*-(4-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)butyl)acetamide or a salt thereof; optionally substituted *N*-(4-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)butyl)-stearamide or a salt thereof; optionally substituted 2-(ethoxymethyl)-1-methyl-9-(2-morpholinoethoxy)-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted 2-(ethoxymethyl)-1-methyl-9-((tetrahydrofuran-3-yl)oxy)-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted 2-(ethoxymethyl)-1-methyl-9-(pyrrolidin-3-yloxy)-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted 2-(ethoxymethyl)-1-methyl-9-(piperidin-4-yloxy)-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted *N*-(3-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)propyl)palmitamide or a salt thereof; optionally substituted *N*-(4-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)butyl)palmitamide or a salt thereof; optionally substituted 9-(3-aminopropoxy)-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted 2-(ethoxymethyl)-9-isopropoxy-1-methyl-1*H*-imidazo[4,5-c]quinolin-4-amine or a salt thereof; optionally substituted 1-((4-amino-2-(ethoxymethyl)-1-methyl-1*H*-imidazo[4,5-c]quinolin-9-yl)oxy)-2-methylpropan-2-ol or a salt thereof; optionally substituted 2-(ethoxymethyl)-3,4-dihydro-5-oxa-1,2a,9-

triazanaphtho[2,1,8-cde]azulen-10-amine or a salt thereof; optionally substituted (R)-2-(10-amino-2-(ethoxymethyl)-3,4-dihydro-5-oxa-1,2a,9-triazanaphtho[2,1,8-cde]azulen-3-yl)propan-2-ol or a salt thereof; optionally substituted (S)-2-(10-amino-2-(ethoxymethyl)-3,4-dihydro-5-oxa-1,2a,9-triazanaphtho[2,1,8-cde]azulen-3-yl)propan-2-ol or a salt thereof; optionally substituted (S)-2-amino-12-(ethoxymethyl)-6-methyl-6,7-dihydro-5H-3,4-(azenometheno)[1,5]oxazocino[4,3,2-de]quinolin-6-ol or a salt thereof; optionally substituted (R)-2-amino-12-(ethoxymethyl)-6-methyl-6,7-dihydro-5H-3,4-(azenometheno)[1,5]oxazocino[4,3,2-de]quinolin-6-ol or a salt thereof; optionally substituted (R)-2-amino-12-(ethoxymethyl)-6,7-dihydro-5H-3,4-(azenometheno)[1,5]oxazocino[4,3,2-de]quinolin-6-ol or a salt thereof; optionally substituted (S)-2-amino-12-(ethoxymethyl)-6,7-dihydro-5H-3,4-(azenometheno)[1,5]oxazocino-[4,3,2-de]quinolin-6-ol or a salt thereof; optionally substituted 2-amino-12-(ethoxymethyl)-5H-3,4-(azenometheno)[1,5]oxazocino[4,3,2-de]quinolin-6(7H)-one or a salt thereof; or optionally substituted tert-butyl 4-((4-amino-2-(ethoxymethyl)-1-methyl-1H-imidazo[4,5-c]quinolin-9-yl)oxy)piperidine-1-carboxylate or a salt thereof.

37. Use of a compound of any one of claims **1** to **36**, in the manufacture of a medicament for the treatment of viral infection, cancer, or an allergic disease.

38. The use of claim **37**, wherein the viral infection comprises HCV infection.

39. A dosage form suitable to be administered to a mammal, comprising a compound of any one of claims **1** to **36**.